Hims & Hers stock skyrockets 40% as Novo Nordisk ends feud, agrees to sell Ozempic and Wegovy on platform

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.